Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $7.38.

A number of analysts recently commented on the company. Wells Fargo & Company increased their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. TD Cowen started coverage on Maravai LifeSciences in a research note on Monday, October 5th. They issued a “buy” rating and a $9.00 price objective for the company. UBS Group upped their price objective on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research note on Wednesday, September 9th. Finally, Wall Street Zen lowered Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th.

Maravai LifeSciences Trading Down 0.5%

Shares of MRVI stock opened at $8.46 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of -16.27 and a beta of 0.54. Maravai LifeSciences has a 52-week low of $2.55 and a 52-week high of $9.42. The company has a 50-day simple moving average of $7.51 and a two-hundred day simple moving average of $5.22.

Maravai LifeSciences (NASDAQ:MRVI) last announced its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%. The firm had revenue of $51.44 million for the quarter, compared to the consensus estimate of $48.67 million. Research analysts anticipate that Maravai LifeSciences will post -0.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Maravai LifeSciences

Institutional investors have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue bought a new position in Maravai LifeSciences during the third quarter valued at about $47,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Maravai LifeSciences during the third quarter worth about $58,000. Royal Bank of Canada raised its position in Maravai LifeSciences by 49.0% in the first quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after acquiring an additional 3,209 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Maravai LifeSciences in the first quarter worth about $37,000. Finally, Squarepoint Ops LLC bought a new stake in Maravai LifeSciences in the second quarter worth about $128,000. Institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.